摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,4-difluoro-N-(2-(1-methoxyethyl)-5-(4-oxo-3-phenyl-3,4-dihydroquinazolin-6-yl)pyridin-3-yl)benzenesulfonamide

中文名称
——
中文别名
——
英文名称
2,4-difluoro-N-(2-(1-methoxyethyl)-5-(4-oxo-3-phenyl-3,4-dihydroquinazolin-6-yl)pyridin-3-yl)benzenesulfonamide
英文别名
2,4-difluoro-N-[2-(1-methoxyethyl)-5-(4-oxo-3-phenylquinazolin-6-yl)pyridin-3-yl]benzenesulfonamide
2,4-difluoro-N-(2-(1-methoxyethyl)-5-(4-oxo-3-phenyl-3,4-dihydroquinazolin-6-yl)pyridin-3-yl)benzenesulfonamide化学式
CAS
——
化学式
C28H22F2N4O4S
mdl
——
分子量
548.57
InChiKey
VWSZUAJSBVGFSK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    39
  • 可旋转键数:
    7
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.11
  • 拓扑面积:
    109
  • 氢给体数:
    1
  • 氢受体数:
    9

反应信息

  • 作为产物:
    参考文献:
    名称:
    Concise SAR Exploration Based on the “Head-to-Tail” Approach: Discovery of PI4KIIIα Inhibitors Bearing Diverse Scaffolds
    摘要:
    In typical kinase inhibitor programs, a hinge binder showing best potency with preferential specificity is initially selected, followed by fine-tuning of the accompanying substituents on its core module. A shortcoming of this approach is that the exclusive focus on a single chemotype can endanger all the analogues in the series if a critical shortcoming is revealed. Thus, an early evaluation of structure activity relationships (SARs) can mitigate unforeseen outcomes within a series of multiple compounds, although there have been very few examples to follow such a policy. PI4KIII alpha is one of four mammalian phosphatidylinositol-4 kinases and has recently drawn significant attention as an emerging target for hepatitis C virus (HCV) treatment. In this letter, a novel "head-to-tail" approach to discover a diverse set of PI4KIII alpha inhibitors is reported. We believe this method will generate distinct core scaffolds, a rational strategy to circumvent potential risks in general kinase programs.
    DOI:
    10.1021/acsmedchemlett.6b00232
点击查看最新优质反应信息